‘‘(2) CONSULTATION.—In establishing the uni-
form reporting criteria for the Registry, the Director 
of the Centers for Disease Control and Prevention 
shall consult with the Administrator, State and local 
medical examiners, prescribing physicians, hospitals, 
and any other organization that the Director deter-
mines is appropriate for purposes of this subsection. 
‘‘(3) REQUIREMENTS.—The registry shall be 
designed as a uniform reporting system for opioid- 
related deaths and shall require the reporting of in-
formation with respect to such deaths, including— 
‘‘(A) the particular drug formulation used 
at the time of death; 
‘‘(B) the dosage level; 
‘‘(C) a description of the circumstances 
surrounding the death in relation to the rec-
ommended dosage involved; 
‘‘(D) a disclosure of whether the medica-
tion involved can be traced back to a physi-
cian’s prescription; 
‘‘(E) a disclosure of whether the individual 
was in an opioid treatment program at the time 
of death; 
‘‘(F) the age and sex of the individual; and 
VerDate Mar 15 2010 
22:30 Feb 21, 2013
Jkt 029200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H672.IH
H672
TKELLEY on DSK3SPTVN1PROD with BILLS
‘‘(G) other non-personal information such 
as that included in filed National Association of 
Medical Examiners Pediatric Toxicology Reg-
istry case reports as required under the privacy 
standard for the de-identification of health in-
formation pursuant to the regulations contained 
in part 164 of title 45, Code of Federal Regula-
tions. 
‘‘(4) AUTHORIZATION.—There is authorized to 
be appropriated $5,000,000 for each of fiscal years 
2014 through 2018 to carry out this subsection. 
‘‘(c) REPORT
ON REGISTRY INFORMATION.—Not 
later than the January 1 of the first fiscal year beginning 
2 years after the date of enactment of this section, and 
each January 1 thereafter, the Director of the Centers for 
Disease Control and Prevention shall submit to the Sec-
retary a report, based on information contained in the 
Registry described in subsection (b), concerning the num-
ber of methadone-related deaths in the United States for 
the year for which the report is submitted.’’. 
SEC. 10. ADDITIONAL REPORTING. 
Part A of title V of the Public Health Service Act 
(42 U.S.C. 290aa et seq.), as amended by section 9, is 
further amended by adding at the end the following: 
VerDate Mar 15 2010 
22:30 Feb 21, 2013
Jkt 029200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H672.IH
H672
TKELLEY on DSK3SPTVN1PROD with BILLS
‘‘SEC. 506F. ADDITIONAL REPORTING. 
‘‘(a) REPORT ON METHADONE USAGE.— 
‘‘(1) IN GENERAL.—Not later than January 1 
of the first fiscal year beginning 2 years after the 
date of enactment of this section, and each January 
1 thereafter, the Administrator and the Commis-
sioner of Food and Drugs shall submit to the Sec-
retary a report containing detailed statistics on 
methadone usage for opioid treatment and pain 
management. Such statistics shall include— 
‘‘(A) information on the distribution of 
prescribed doses of methadone at federally 
qualified health centers, opioid treatment clin-
ics, other health-related clinics, physician of-
fices, pharmacies, and hospitals; and 
‘‘(B) information relating to adverse health 
events resulting from such methadone usage. 
‘‘(2) AVAILABILITY
OF
INFORMATION.—The 
Secretary shall make the reports submitted under 
paragraph (1) available to the general public, includ-
ing through the use of the Internet website of the 
Department of Health and Human Services. 
‘‘(b) ANNUAL REPORT
ON EFFECTIVENESS.—Not 
later than September 30, 2014, and annually thereafter 
until September 30, 2016, the Secretary shall submit to 
the appropriate committees of Congress, a report con-
VerDate Mar 15 2010 
22:30 Feb 21, 2013
Jkt 029200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H672.IH
H672
TKELLEY on DSK3SPTVN1PROD with BILLS
cerning the effectiveness of the methadone maintenance 
therapy program. Such report shall evaluate the success 
of efforts to reduce opioid addiction and methadone-re-
lated deaths, including the impact of health care provider 
and patient education. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
such sums as may be necessary for each of fiscal years 
2014 through 2018.’’. 
SEC. 11. DEVELOPMENT OF PRESCRIPTION DRUG ABUSE 
PREVENTION 
AND 
TREATMENT 
QUALITY 
MEASURES ACROSS EACH RELEVANT PRO-
VIDER SETTING. 
Subpart I of part D of title IX of the Public Health 
Service Act (42 U.S.C. 299b-31 et seq.) is amended by 
adding at the end the following: 
‘‘SEC. 932. DEVELOPMENT OF PRESCRIPTION DRUG ABUSE 
PREVENTION 
AND 
TREATMENT 
QUALITY 
MEASURES ACROSS EACH RELEVANT PRO-
VIDER SETTING. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Agency for Healthcare Research and 
Quality and in consultation with the Director of the Cen-
ters for Disease Control and Prevention, the Adminis-
trator of the Substance Abuse and Mental Health Services 
VerDate Mar 15 2010 
22:30 Feb 21, 2013
Jkt 029200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H672.IH
H672
TKELLEY on DSK3SPTVN1PROD with BILLS
Administration, and the Director of the Centers for Medi-
care & Medicaid Services, shall require the development 
and application of specific prescription drug abuse preven-
tion and treatment quality measures for each relevant 
health care provider setting, as identified by the Director. 
‘‘(b) DISSEMINATION.—Not later than April 1, 2016, 
the Secretary shall disseminate the quality measure re-
quirements developed under subsection (a) to all affected 
providers. 
‘‘(c) TYPES OF MEASURES.—Quality measures devel-
oped under this section may be structure-oriented (such 
as the required presence of a hospital-based treatment 
program), process-oriented (such as requiring patients to 
be informed of the addictive qualities of the medication 
being prescribed), or outcome-oriented (such as assessing 
family satisfaction with care).’’. 
Æ 
VerDate Mar 15 2010 
22:30 Feb 21, 2013
Jkt 029200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6301
E:\BILLS\H672.IH
H672
TKELLEY on DSK3SPTVN1PROD with BILLS